We envision a new age in healthcare, wherein a single highly multiplexed, multi-analyte assay with single-cell sensitivity not only replaces thousands of targeted diagnostics for individual cancers, infectious diseases, metabolic conditions and other rare or common disorders, but also generates actionable individualized information to streamline clinical intervention strategies.
Chief Executive Officer, Co-Founder
Nik is a Professor and Director of Human Biology at the J. Craig Venter Institute and an adjunct Professor at the University of California, San Diego. Nik's interests and expertise are in quantitative human genetics and integrated approaches to complex biological and medical problems, especially the design and implementation of methodologies to dissect the determinants of complex traits and diseases. He has published over 450 scientific articles and book chapters on the analysis of complex, multifactorial traits and diseases. Nik earned the B.A. in Philosophy, M.A. in Philosophy, M.A. in Statistics, and Ph.D. in Epidemiology, all from the University of Michigan in Ann Arbor.
Chief Technology Officer, Co-Founder
Devon has trained as a synthetic and supramolecular chemist under the guidance of Fraser Stoddart and molecular biology under the guidance of Ann Hirsch at University of California, Los Angeles. Devon’s Ph.D thesis work on the manipulation of proteins and nucleic acids with Reza Ghadiri at The Scripps Research Institute allowed him to develop methodologies for the programmatic control of enzymatic activity using protein-oligonucleotides conjugates. Devon demonstrated that programmable control of enzymatic activity could be directly targeted on the surface of living cells. Devon’s interest lies in the improving the targeting specificity of cancer therapeutics using combinatorial engineering.
Chief Science Officer, Co-Founder
Kit received his PhD from The Scripps Research Institute, where he co-authored 16 scientific papers, contributed ~2000 data sets to Gene Expression Omnibus, and received fellowships from both CIRM and Autism Speaks. With a passion for biology, biotechnology, and systems biology, Kit is determined to realize MYi's vision of personalized medicine along side his group of talented and inspiring co-founders.
Chief Business Officer
Maria is the Principal and General Partner of private equity group Ridgetop Health. She brings 20 years of experience in the healthcare and pharmaceutical industries. She held senior roles in business development, strategic planning, and marketing at Novartis and Sandoz Latin America. Maria also spent seven years in investment banking at Morgan Stanley. She trained as a certified accountant and audit manager at PricewaterhouseCoopers and holds an MPH from Columbia University and a BSc in Human Genetics from the University College London.
Interested in joining our growing team? Contact us!